

## Preparation, X-ray structure and reactivity of a stable glycosyl iodide

Jamie Bickley,<sup>a</sup> Jennifer A. Cottrell,<sup>a</sup> John R. Ferguson,<sup>c</sup> Robert A. Field,<sup>b</sup> John R. Harding,<sup>d</sup> David L. Hughes,<sup>b</sup> K. P. Ravindranathan Kartha,<sup>b</sup> Jayne L. Law,<sup>c</sup> Feodor Scheinmann<sup>c</sup> and Andrew V. Stachulski<sup>\*a</sup>

<sup>a</sup> The Robert Robinson Laboratories, Department of Chemistry, University of Liverpool, Liverpool, UK L69 7ZD. E-mail: stachuls@liv.ac.uk; Fax: 44 (0)151 794 3588; Tel: 44 (0)151 794 3542

<sup>b</sup> Centre for Carbohydrate Chemistry, School of Chemical Sciences and Pharmacy, University of East Anglia, Norwich, UK NR4 7TJ

<sup>c</sup> Ultrafine UFC Ltd., Synergy House, Guildhall Close, Manchester Science Park, Manchester, UK M15 6SY

<sup>d</sup> AstraZeneca UK Ltd., Drug Metabolism and Pharmacokinetics Department, Mereside, Alderley Park, Macclesfield, Cheshire, UK SK10 4TG


Received (in Cambridge, UK) 7th March 2003, Accepted 2nd April 2003

First published as an Advance Article on the web 30th April 2003

Highly selective reaction of methyl tetra-*O*-pivaloyl- $\beta$ -D-glucopyranuronate **2** with iodotrimethylsilane or (Me<sub>3</sub>Si)<sub>2</sub> and I<sub>2</sub> affords, in excellent yield, the 'disarmed' glycosyl iodide **1** which has good stability at 20 °C and excellent stability at 0 °C; the X-ray crystal structure of **1** is described, along with a comparison of its utility as a glycosyl donor to that of the corresponding bromide.

Although a very wide range of glycosyl donors are now available, including in particular thioglycosides,<sup>1</sup> anomeric trichloroacetimidates,<sup>2</sup> sulfoxides<sup>3</sup> and pentenyl glycosides,<sup>4</sup> anomeric halosugars are still commonly employed in glycosidation reactions. Traditionally glycosyl bromides have been used, activated by heavy metal salts (usually those of Ag and Hg, occasionally of Cd), the classical Koenigs–Knorr conditions.<sup>5</sup> Within the last decade it has been shown that iodine reagents are effective alternatives to the heavy metals, for both 'armed' and 'disarmed' cases, and are effective for other anomeric leaving groups.<sup>6,7</sup> It has been traditionally held<sup>8</sup> that glycosyl iodides are too difficult to prepare, and too unstable, to be useful glycosyl donors. A number of publications have appeared regarding their preparation, nevertheless, and others have cited them as reactive *in situ* intermediates.<sup>9</sup> In particular Gervay *et al.*<sup>10,11</sup> have shown that 'armed' glycosyl iodides will react with a variety of nucleophiles and have reinvestigated 'disarmed' idosugars without isolating them.<sup>11</sup>

As is widely understood, substitution critically affects reactivity and stability in all carbohydrate derivatives. We now report that the pivaloate-protected glycosyl iodide **1**, derived from glucuronolactone, is formed in high yield and under mild conditions from the  $\beta$ -tetrapivaloate **2**<sup>12</sup> and moreover possesses excellent stability. We also present the X-ray structure of **1** and briefly compare its reactivity to that of the corresponding bromosugar **3**.<sup>12</sup>



1 X =  $\alpha$ -I

2 X =  $\beta$ -O<sub>2</sub>CCMe<sub>3</sub>

3 X =  $\alpha$ -Br

5 X =  $\beta$ -O(CH<sub>2</sub>)<sub>2</sub>Ph

Various methods for the conversion of anomeric ester **2** to glycosyl iodide **1** were studied, as summarised in Table 1. Marginally best was the hexamethyldisilane–I<sub>2</sub> method,<sup>15</sup> which generates Me<sub>3</sub>SiI *in situ*, though the Me<sub>3</sub>SiI procedure also afforded a 90%+ yield.<sup>10</sup> The chemical stability of **1** is excellent. At 0 °C it is stable for well over one year if kept dry

and away from light (best stored in a Nalgene bottle); at 20 °C it remains unchanged after many months.

The glycosyl iodide **1** was readily crystallised from hexane, mp 104–105 °C and gave crystals suitable for X-ray structure determination (pale yellow prisms, orthorhombic).<sup>17</sup> The structure of **1** is presented in Fig. 1.

It can be seen that **1** adopts a normal 'chair' <sup>4</sup>C<sub>1</sub> conformation: its structure differs in minor respects from that of the bromosugar **3**. The O–C(1) bond shows characteristic bond shortening (1.398 Å, identical to the O–C(1) bond in **3**: typical sp<sup>3</sup>C–O, 1.43 Å), and the C(1)–I bond characteristic lengthening (2.22 Å: typical sp<sup>3</sup>C–I, 2.16 Å), owing to the anomeric effect.

Table 1 Preparative methods for the anomeric idosugar **1**

Reagents, conditions	Time/h	Yield <sup>a</sup> (%)
KI, BF <sub>3</sub> ·Et <sub>2</sub> O, MeCN, <b>2</b> , 80 °C <sup>13,14</sup>	3	67
Me <sub>3</sub> SiI, MeCN, <b>2</b> , 50 °C <sup>9a,10</sup>	2.75	91
(Me <sub>3</sub> Si) <sub>2</sub> , I <sub>2</sub> , CH <sub>2</sub> Cl <sub>2</sub> , <b>2</b> , 20 °C <sup>15</sup>	5	92
PhSiMe <sub>3</sub> , I <sub>2</sub> , MeCN, <b>2</b> , 50 °C <sup>16</sup>	1.7	53

<sup>a</sup> After chromatography and/or crystallisation.





Fig. 1 X-Ray structure of idosugar **1**, (top) in plan, (bottom) in elevation showing the 'chair'.



Scheme 1

The conformations of the C(2) and C(5)/C(6) substituents, however, differ between **1** and **3**, probably owing to the relative sizes of the Br/I atoms and packing effects. The  $^1\text{H}$  NMR spectra of the two halosugars also show some differences. Both the H(2)–H(3) axial–axial and H(1)–H(2) axial–equatorial coupling constants in **1**, respectively 9.8 and 4.4 Hz,<sup>17</sup> fall within the typical pyranose range, but very interestingly the chemical shift of the 2-H is significantly lower in **1** than in **3**, whereas the chemical shift of the 1-H is higher in **1** than in **3**. A similar trend has been noted before in anomeric iodosugars of the galactose series:<sup>15</sup> moreover the difference in chemical shifts of the anomeric protons of **1** and **3**, at 0.36 ppm, is comparable to that between the anomeric protons of the parent 2-bromo- and 2-iodo-tetrahydropyrans (0.46 ppm) as given by Anderson and Sepp.<sup>18</sup>

Because of the continuing interest in morphine-6-glucuronide **4** as an analgesic more potent and better tolerated than morphine itself,<sup>13,19</sup> the glycosyl donor ability of **1** was studied in this context (Scheme 1). In a model experiment, **1** (1 eq.) proved to be a suitable donor for glycosidation of 2-phenylethanol (1.5 eq.) using  $\text{ZnCl}_2$  (1.1 eq.) as catalyst in 1,2-dichloroethane (20 h, 20 °C); glucuronate ester **5**<sup>20</sup> was isolated in 56% yield (unoptimised). Reaction of 3-*O*-pivaloyl morphine **6**<sup>19c</sup> with **1** (1.1 eq.) mediated by  $\text{I}_2$  (2.5 eq.) with no other catalyst afforded glucuronate ester **7** (55% after chromatography) after 60 h.<sup>13,21</sup> The yield compares well to that obtained using the trichloroacetimidate method<sup>22</sup> and the product was identical to **7** prepared in that way; moreover only a 10% excess of **1** is required. By contrast, reaction of **6** with the bromosugar **3** (which afforded typically 80–85% yields in glycosidation of primary alcohol acceptors)<sup>20</sup> under comparable conditions gave only a 20% yield of **7**. Finally, base-catalysed hydrolysis of **7** led cleanly to morphine-6-glucuronide **4**<sup>19c</sup> in 85% yield.

In summary, we have characterised a highly stable ‘disarmed’ glycosyl iodide, namely **1**, and shown it to possess a typical chair structure by X-ray diffraction. This represents the first crystal structure for this class of molecule. Furthermore, we have shown glycosyl iodide **1** to be an effective glycosyl donor in reactions with both a primary and a secondary alcohol acceptor.

We are grateful to the EPSRC and Astra Zeneca PLC for an industrial CASE studentship (to J. A. C.) and to Professor A. J. Kirby (University of Cambridge) for valuable comments.

## Notes and references

- (a) P. Fuegedi, P. J. Garegg, H. Loenn and T. Norberg, *Glycoconjugate J.*, 1987, **4**, 97; (b) F. Dasgupta and P. J. Garegg, *Carbohydr. Res.*, 1988, **177**, C13.

- (a) R.R. Schmidt, *Angew. Chem., Int. Ed. Engl.*, 1986, **5**, 212; (b) W. Kinzy and R. R. Schmidt, *Adv. Carbohydr. Chem. Biochem.*, 1994, **50**, 21.
- (a) D. Kahne, S. Walker, Y. Cheng and D. van Engen, *J. Am. Chem. Soc.*, 1989, **111**, 6881; (b) L. Yan and D. Kahne, *J. Am. Chem. Soc.*, 1996, **118**, 9239.
- (a) D. R. Mootoo, V. Date and B. Fraser-Reid, *J. Am. Chem. Soc.*, 1988, **110**, 2662; (b) A. J. Ratcliffe, P. Konradsson and B. Fraser-Reid, *J. Am. Chem. Soc.*, 1990, **112**, 5665.
- (a) W. Koenigs and E. Knorr, *Chem. Ber.*, 1901, **34**, 957; (b) B. Helferich and K. F. Wedeneyer, *Liebigs Ann. Chem.*, 1949, **563**, 139; (c) R. B. Conrow and S. Bernstein, *J. Org. Chem.*, 1971, **36**, 863; (d) Summarised by H. Paulsen, in *Modern Methods in Carbohydrate Synthesis*, S. H. Khan and R. A. O'Neill, eds., Harwood Academic Publishers, The Netherlands, 1996, pp. 1–19.
- K. P. R. Kartha, M. Aloui and R. A. Field, *Tetrahedron Lett.*, 1996, **37**, 8807.
- K. P. R. Kartha, T. S. Karkkainen, S. J. Marsh and R. A. Field, *Synlett.*, 2001, 260.
- For example P. M. Collins and R. J. Ferrier, *Monosaccharides*, J. Wiley, Chichester, 1995, p. 163.
- Especially: (a) A. Klemm and M. Bieber, *Liebigs Ann. Chem.*, 1984, 1052; (b) B. Ernst and T. Winkler, *Tetrahedron Lett.*, 1989, **30**, 3081; (c) U. Schmid and H. Waldmann, *Tetrahedron Lett.*, 1996, **37**, 3837; (d) S. M. Chervin, P. Abada and M. Koreeda, *Org. Lett.*, 2000, **2**, 369.
- J. Gervay and M. J. Hadd, *J. Org. Chem.*, 1997, **62**, 6961.
- (a) J. Gervay, T. N. Nguyen and M. J. Hadd, *Carbohydr. Res.*, 1997, **300**, 119; (b) S. N. Lam and J. Gervay-Hague, *Carbohydr. Res.*, 2002, **337**, 1953; (c) J. Gervay, *Glycosyl Iodides in Organic Synthesis*, in *Organic Synthesis: Theory and Applications*, JAI Press Inc., New York, 1998, vol. **4**, pp. 121–153.
- J. Vlahov and G. Snatzke, *Liebigs Ann. Chem.*, 1983, 570.
- J. R. Ferguson, J. L. Law, F. Scheinmann and A. V. Stachulski, *British Patent Application*, No. 9914382.8, to Ultrafine UFC Ltd., July 1999.
- Cf.* the corresponding (and much less stable) triacetate: R. T. Brown, F. Scheinmann and A. V. Stachulski, *J. Chem. Res. (S)*, 1997, 370.
- K. P. R. Kartha and R. A. Field, *Carbohydr. Lett.*, 1998, **3**, 179.
- T.-L. Ho and G. A. Olah, *Synthesis*, 1977, 417.
- Full characterisation was obtained for **1**.  $^1\text{H}$  NMR of **1**:  $\delta_{\text{H}}$  (400 MHz,  $\text{CDCl}_3$ ) 1.13, 1.18 and 1.20 (27 H, 3 s,  $3 \times \text{Me}_3\text{C}$ ), 3.74 (3 H, s,  $\text{CH}_3\text{O}$ ), 4.27 (1 H, dd,  $J = 9.8$  and 4.4 Hz, 2-H), 4.37 (1 H, d,  $J = 10.3$  Hz, 5-H), 5.31 (1 H, t, 3-H), 5.61 (1 H, t, 4-H) and 7.01 (1 H, d,  $J = 4.4$  Hz, 1-H).  $^{13}\text{C}$  NMR:  $\delta_{\text{C}}$  (100 MHz,  $\text{CDCl}_3$ ) 27.42, 27.51, 38.95, 39.12, 39.17, 53.34, 68.31, 70.37, 70.94, 71.70, 75.49, 167.04, 176.99 and 177.30. Found: C, 46.4; H, 6.25;  $\text{Mn}^+$ , 593.1230.  $\text{C}_{22}\text{H}_{35}\text{IO}_9$  requires C, 46.3; H, 6.20%;  $\text{C}_{22}\text{H}_{35}\text{IO}_9\text{Na}$  requires  $m/z$ , 593.1224. *Crystal data*:  $\text{C}_{22}\text{H}_{35}\text{IO}_9$ ,  $M_w = 570.40$ , orthorhombic, space group  $P2_12_12_1$ ,  $a = 9.6982(16)$ ,  $b = 11.4712(19)$ ,  $c = 22.658(4)$  Å,  $T = 100$  K,  $U = 2520.7(7)$  Å<sup>3</sup>,  $Z = 4$ ,  $\mu(\text{Mo-K}\alpha) = 1.317$  mm<sup>-1</sup>, 4595 reflections collected, 3911 unique,  $R_{\text{int}} = 0.0413$ , final  $wR(F^2) = 0.0525$  (all data). Absolute structure  $Flack^{24} = 0.006(16)$ . CCDC reference number 205813. See <http://www.rsc.org/suppdata/cc/b3/b302629a/> for crystallographic data in CIF or other electronic format.
- NMR of **3**:  $\delta_{\text{H}}$  (400 MHz,  $\text{CDCl}_3$ ) 1.14, 1.17 and 1.19 (27 H, 3 s,  $3 \times \text{Me}_3\text{C}$ ), 3.74 (3 H, s,  $\text{CH}_3\text{O}$ ), 4.59 (1 H, d,  $J = 10.3$  Hz, 5-H), 4.85 (1 H, dd,  $J = 9.9$  and 4.1 Hz, 2-H), 5.28 (1 H, t, 3-H), 5.69 (1 H, t, 4-H) and 6.66 (1 H, d,  $J = 4.1$  Hz, 1-H).
- C. B. Anderson and D. T. Sepp, *J. Org. Chem.*, 1967, **32**, 607.
- (a) R. J. Osborne, S. P. Joel, D. Trew and M. Slevin, *Lancet*, 1988, i: 828; (b) R. J. Osborne, P. I. Thompson, S. P. Joel, D. Trew, N. Patel and M. Slevin, *Br. J. Clin. Pharmacol.*, 1992, **34**, 130; (c) F. Scheinmann, K. W. Lumbard, R. T. Brown and S. P. Mayalar, *International Patent*, WO 93/3051, 1993, to Ultrafine UFC Ltd.
- A. V. Stachulski, *Tetrahedron Lett.*, 2001, **42**, 6611.
- It was known that  $\text{ZnBr}_2$  in dichloromethane at reflux was a suitable catalyst for the glucuronidation of 3-acylmorphines using a glycosyl bromide: I. Rukhman, G. Nisnevich and A. L. Gutman, *Tetrahedron*, 2001, **57**, 1083.
- R. T. Brown, N. E. Carter, F. Scheinmann and K. W. Lumbard, *Tetrahedron Lett.*, 1995, **36**, 8661.
- G. M. Sheldrick, *SHELX97*, Crystal structure determination program, University of Gottingen, Gottingen, Germany, 1997.
- H. D. Flack, *Acta Crystallogr. Sect. A Fundam. Crystallogr.*, 1983, **39**, 876.